The introduction of anti-EGFR antibodies and EGFR tyrosine kinase inhibitors (TKIs) in clinical practice drastically improved the prognosis of patients affected by various cancer types, especially lung cancer, the first leading cause of cancer death worldwide. Here, EGFR is linked to lung cancer.